Discontinuation of Statin Therapy Deadly For Rheumatoid Arthritis Patients?

.

Discontinuation of Statin Therapy Deadly For Rheumatoid Arthritis Patients?

A new study proposed has underlined that people who are diagnosed of Rheumatoid Arthritis (RA), in case, discontinue their statin therapy then, there are higher chances that they even fall to severe heart problems. The study should actually be considered as a warning for those suffering from rheumatoid arthritis.

The study conducted by American College of Rheumatology, was carried out for almost four years, analyzing people suffering from RA. During the research, it was observed that around 45% of people with RA discontinued their drugs statin at least once in the four years of the research.

As a consequence, 198 deaths were reported to be due to cardiovascular diseases out of the 467 deaths in total. It was hence, declared that patients, who are suffering from RA and are prescribed to undergo the therapy, should not discontinue it, else it can lead to cardiovascular diseases.

Lead author Mary De Vera, of the University Of British Columbia School of Population & Public Health and Arthritis Research Centre of Canada, said "Our study findings emphasise the importance of medication compliance in RA patients who are prescribed statins”.

Another study of the same kind conducted by Vancouver, Montreal and Boston researchers, also confirmed with their findings that RA patients who quit statin drugs had 79 % increased risk of death.


Latest News

Agreement between Amazon.com and Simon & Schuster to be Advantageous for Both th
Nadella gets a Pay Package Worth $84M from Microsoft; Announces Help in Ebola Re
Slowest Growth in China since the 2008/9 Global Crisis
New Models of iPhone Helps Apple to Achieve a Record Profit
Reheating pasta makes it healthier
Google Glass’ first addict
High-fat meals can cause obesity in men before women
Fujifilm shares go up after Ebola drug announcement
QEP Pipeline Assets Bought by Tesoro in a $2.5 Billion Deal
Adidas’s Reebok to Get a $2.2 billion Bid from Investors
Survey Reveals Slow Wage Increases in the U.S
Eurozone’s Low Performance Draw Mixed Reactions